Vivani Medical obtains Australian approval to begin GLP-1 implant trial [Yahoo! Finance]
Vivani Medical, Inc. (VANI)
Company Research
Source: Yahoo! Finance
Committee (HREC) for the initiation of a first-in-human clinical trial in Australia for its glucagon-like peptide 1 (GLP-1) implant, designed for obese and overweight individuals. The Therapeutic Goods Administration (TGA) has also formally acknowledged the trial. Named LIBERATE-1, the trial will assess the tolerability, safety and pharmacokinetic profile of the company's exenatide implant. This marks the first clinical use of Vivani's NanoPortal drug implant technology. The study will randomise participants to receive either Vivani's exenatide implant, weekly exenatide injections or semaglutide injections after an initial eight-week titration period with semaglutide. Participants in the trial will undergo an eight-week titration with semaglutide injections before being randomised into one of three treatment arms. Each group will comprise eight subjects, and the trial aims to measure changes in weight over a nine-week treatment period. The study's commencement is slated for
Show less
Read more
Impact Snapshot
Event Time:
VANI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VANI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VANI alerts
High impacting Vivani Medical, Inc. news events
Weekly update
A roundup of the hottest topics
VANI
News
- Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial ResultsBusiness Wire
- Brain Implant Startups Aim to Bring Vision Back to The Blind [Yahoo! Finance]Yahoo! Finance
- Vivani Medical, Inc. (NASDAQ: VANI) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $3.00 price target on the stock.MarketBeat
- Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024Business Wire
- Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in AustraliaBusiness Wire
VANI
Analyst Actions
- 11/7/24 - HC Wainwright
VANI
Sec Filings
- 11/13/24 - Form 4
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- VANI's page on the SEC website